

COVID-19 Q&A Hour for Long Term Care



WASHINGTON STATE DEPARTMENT OF HEALTH

Healthcare-Associated Infections (HAI) Program

Shoreline, WA

Housekeeping



Attendees will be in listen only mode



Self-mute your lines when not speaking



Type questions into the question window. Please include the type of facility you are from in your question (e.g., NH) and indicate your county.



Nursing Home

Participants from long-term care, regulatory, public health



No confidential information presented or discussed. This is an educational webinar and does not constitute legal advice.



Local guidance may differ, please consult with your Local Health Jurisdiction (LHJ):

<https://www.doh.wa.gov/AboutUs/PublicHealthSystem/LocalHealthJurisdictions>

This is the LTC COVID-19 Q&A Hour!

A chance to connect, ask questions, and learn about the COVID-19 response and infection prevention guidance



Where Can I Find the Q & A Document?

Posted every Wednesday

- Washington Health Care Association:

<https://www.whca.org/washington-department-of-health-covid-19-qa-session/>

- LeadingAge Washington:

FAQ emailed to members – Administrators, Directors of Nursing and Staff Development Coordinators

- Adult Family Home Council:

<https://adultfamilyhomecouncil.org/covid-19/>

Panelists




Send Us Your Questions Ahead of Time

Subject Line:
COVID Q&A

Email:
HAI-COVID@doh.wa.gov

Due by: COB Tuesday





WASHINGTON STATE DEPARTMENT OF HEALTH

ICAR PROGRAM DETAILS

Our free, non-regulatory ICARs provide facilities with infection prevention recommendations and resources on how to keep residents and staff safe.

What We Do

- Provide support with an infection prevention expert
- Assist with addressing gaps in your current infection control protocols for COVID-19 or other infections
- Offer up-to-date guidance and resources

Who We Serve

- Long Term Care Facilities (Assisted, Skilled, Behavioral Health, Nursing facilities, and Adult Family Homes)
- Outpatient Settings
- Acute and Critical Access Hospitals

To Learn More or Schedule an In-Person or Virtual Visit:

<http://doh.wa.gov/ICAR>

Contact Us:

HAI-FieldTeam@doh.wa.gov (General)



In Partnership With

- Local Health Jurisdictions
- LeadingAge Washington
- Washington Health Care Association
- Adult Family Home Council of WA State
- Washington State Hospital Association



WASHINGTON STATE DEPARTMENT OF HEALTH

HAI-AR SECTION EMAIL ADDRESSES

Please refer to the table below to find the email most appropriate for your needs

Email Path	Description
HAI@doh.wa.gov	General healthcare associated infection questions
HAI-Covid@doh.wa.gov	COVID19-specific healthcare associated infection questions
HAIEpiOutbreakTeam@doh.wa.gov	Epidemiological outbreak assistance and healthcare associated infection questions
HAI-FieldTeam@doh.wa.gov	Schedule an ICAR for your facility
HAI-FITTesting@doh.wa.gov	Respiratory Protection related questions www.doh.wa.gov/ltrcpp

Flu Resources

- DOH Resources for Public Health and Healthcare Providers:
 - <https://www.doh.wa.gov/ForPublicHealthandHealthcareProviders/PublicHealthSystemResourcesandServices/Immunization/InfluenzaFluInformation>
- Communications Toolkit:
 - toolkits.knockoutflu.org
- Flu Fighter Award – enrollment extended to 2/15/22 with awards in August 2022:
 - <https://www.surveymonkey.com/r/Y85W7RH>
- Washington State Flu Report:
 - www.doh.wa.gov/Portals/1/Documents/5100/420-100-FluUpdate.pdf
- CDC Weekly Flu Report:
 - www.cdc.gov/flu/weekly



WA Department of Health's

Project Firstline

PODCAST!

**LIVE on
SoundCloud!**

Scan to listen



or search:

"WA Dept. Health Project Firstline"

**May need to download the SoundCloud App by opening the iOS or Google Play App
Store on your iPhone or Android device.**

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.

Pub #: 420-379

Learn about
Infection Prevention
& Public Health
practices!

Listen as we talk to guests
about the importance and
impact these practices
bring to our lives and the
lives of our community!

Upcoming LTC Q&A Schedule

Please plan to attend these upcoming micro learning sessions!

Today's discussion:

- Therapeutics allocation
- Booster doses

Upcoming micro learning topics -

- Feb 10: Success Story - AFH
- Feb 17 & 24: Respiratory Protection Program
- Mar 3 & 10: How to obtain Respirators and PPE

Updates

CDC Guidance

C-19 Therapeutics allocation process

Current products that are allocated to DOH from HHS/ASPR

Monoclonal antibodies-

REGEN-COV – Regeneron(distribution currently paused)

Bamlanivimab/Etesevimab – Eli Lilly(distribution currently paused)

Sotrovimab – Glaxo-Smith Kline

Evusheld - Astrazeneca

Oral antivirals

Paxlovid – Pfizer

Molnupiravir - Merck

C-19 Therapeutics allocation process

- Sites request allocation from DOH via Smartsheet and request are filled based on available product
- Sites requesting allocation must be registered in the Healthcare Partner Ordering Portal(HPOP)
- Requests are made via Smartsheet or through WAHEALTH
 - [COVID-19 Therapeutic allocation request form](#)
 - <https://wahealth.doh.wa.gov/>
- Sites receiving allocation are required to report on-hand/administered courses daily via HPOP account
- Requests are limited for products that are in limited supply
 - Sotrovimab / Paxlovid

What can you do to get these?

- Ensure that your dispensing pharmacy has an HPOP account
- Ensure that your dispensing pharmacy is requesting an allocation
- Make preparations to administer and or prescribe therapeutics
- Stay informed on therapeutic updates
- Make sure you are aware of the EUA requirements for eligible patients
- If needed, request direct allocation to your site

C-19 Therapeutics guidance/resources

The following resources are available on the DOH Therapeutics website:

<https://www.doh.wa.gov/Emergencies/COVID19/Therapeutics/>

Federal Clinical Resources and Information

- [COVID-19 therapeutics decision aid \(PDF\)](#) (U.S. Office of the Assistant Secretary for Preparedness and Response)
- [Side-by-side overview of mAb therapeutics](#) (ASPR)
- [What's new in treatment guidelines](#) (National Institutes of Health)

State Ordering Guidance

- [Overview of WA State Order Process for COVID-19 Therapeutics](#)

Other Guidance documents

- [Interim Guidance on Monoclonal Antibody Use in Washington](#)
- [Interim DOH Guidance on Prioritization for Use of Molnupiravir](#)
- [Interim DOH Guidance on Prioritization for Use of Paxlovid](#)
- [Interim DOH Guidance on Prioritization for Use of EVUSHELD](#)

Questions?







BOOSTER NEEDED!

Kathy Bay RN, DNP, CENP

LTC-Associated and Likely Associated Cases




Age-Adjusted Rates of COVID-19-Associated Hospitalizations by Vaccination Status in Adults Ages ≥ 18 Years, January–December 2021



CDC Data Tracker, COVID-19 hospitalizations by vaccination status
<https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination>

United States: COVID-19 weekly death rate by vaccination status, All ages

Death rates are calculated as the number of deaths in each group, divided by the total number of people in this group. This is given per 100,000 people.



Source: CDC COVID-19 Response, Epidemiology Task Force

OurWorldInData.org/coronavirus + CC BY

Note: Unvaccinated people have not received any dose. Partially-vaccinated people are excluded. Fully-vaccinated people have received all doses prescribed by the initial vaccination protocol. The mortality rate for the 'All ages' group is age-standardized to account for the different vaccination rates of older and younger people.

Our World in Data, US COVID-19 weekly death rate by vaccination status

<https://ourworldindata.org/covid-deaths-by-vaccination>

Omicron is intrinsically less severe than Delta, but the reduction in risk is much smaller than that provided by vaccines

Risk of a 70-year-old being admitted to ICU with Covid after testing positive, by variant and vaccination status (log scale)



Source: French directorate of research, studies, evaluation and statistics
FT graphic by John Burn-Murdoch / @burnmurdoch
© FT

Financial Times, “Pandemic of the unboosted” – has some interesting data visualizations (two examples below)

<https://www.ft.com/content/03aa46e2-ac3a-4c16-82be-431ea4c43e58>

Vaccine Recommendations

Pfizer-BioNTech ^[1]	Moderna ^[1]	Johnson & Johnson's Janssen ^[1,2]
Ages Recommended 5+ years old	Ages Recommended 18+ years old	Ages Recommended 18+ years old
Primary Series 2 doses ^[3,4] Given 3 weeks (21 days) apart ^[5]	Primary Series 2 doses ^[3] Given 4 weeks (28 days) apart ^[5]	Primary Series 1 dose
Fully Vaccinated 2 weeks after final dose in primary series	Fully Vaccinated 2 weeks after final dose in primary series	Fully Vaccinated 2 weeks after 1st dose
Booster Dose Everyone ages 12+ should get a booster dose at least 5 months after the last dose in their primary series. <ul style="list-style-type: none"> • Teens 12–17 should only get a Pfizer-BioNTech COVID-19 Vaccine booster • Everyone 18+ should get a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) 	Booster Dose Everyone ages 18+ should get a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) at least 5 months after the last dose in their primary series.	Booster Dose Everyone ages 18+ should get a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) at least 2 months after the first dose of J&J/Janssen COVID-19 Vaccine. You may get J&J/Janssen in some situations .

[Stay Up to Date with Your Vaccines | CDC](#)


Long Term Care Facility Booster

- There is support for onsite vaccinations for residents and staff
 - Long Term Care Pharmacy
 - Local Health Jurisdiction
 - Department of Health survey to request help:
 - <https://www.surveymonkey.com/r/DQ5K9WV>
- Onsite support may encourage staff to get vaccinated because of the ease of access

Long-Term
Care COVID-19
Immunization
Champion
Award



U.S. Vaccine Safety Monitoring Systems and Timelines



Source: Advisory Committee on Immunization Practices meeting 08-30-2021; [ACIP August 30, 2021 Presentation Slides | Immunization Practices | CDC](#). Accessed 08-31-2021.

Vaccine Safety


- The vaccines were evaluated in tens of thousands of people during clinical trials
- Pfizer and Moderna vaccines are both fully licensed for adults
- Ongoing safety monitoring is done even with full licensing
- More than 539 million doses of COVID-19 vaccine have been given in the United States

Vaccine Side Effects

ABOUT THE COVID-19 VACCINE

Types of Vaccines (in U.S.)


mRNA



(Pfizer & Moderna)

Most individuals are recommended to receive an additional dose.


VECTOR VIRUS



(J&J/Janssen)

Vaccine Side Effects

In most cases vaccine side effects last 1 to 2 days.



*Thrombosis with thrombocytopenia syndrome
**Guillain-Barre syndrome

GO TO [VACCINE.CHOP.EDU](https://vaccine.chop.edu) FOR MORE INFORMATION.



Source: Vaccine Education Center at CHOP

Questions?



To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.

Q & A Portion

Please type your questions into the question window and tell us what type of facility you are from (e.g., ALF, SNF, AFH) and what county you are in